Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)
Clinical trial NCT02720068 · COMPLETED
Trial details
- NCT number
- NCT02720068
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-05-02
- Primary completion
- 2024-03-15
- Enrollment
- 481
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.